582
KLINICKÁ341804301074588109168189242288347
FARMAKOLOGIE708804301074392139212266313373416475534555599
A13288043010753
FARMACIE1402804301074292139211266317337381
/18048043010757
Klin1880804301077091109157
Farmakol2057804301074278105179220258305325
Farm2402804301074178104179
2019;2601804301074386126164180
33(3):2801804301074385107150171185
20–243006804301074487135175215
/32418043010756
www.klinickafarmakologie.cz4568804301076513320121425327329234035839843647950254457164568672477179183988990895196610061045
241838026012657115
HLAVNÍ341207012670127198263336370
TÉMA733207012657114204274
Imunitně34136501061569110151168200242274
podmíněné63036501063374114168185226258300331
nežádoucí97736501063971106147187228269303321
účinky13143650106397391132167206
inhibitorů15353650106165798116151169201240276317
kontrolních186836501063372114146182222254296313347389
bodů227236501063475115156
kou34362301073989140
manifestací512623010776119169190216262297329372415436
a969623010750
závažností.104162301074589132175215266317353384405422
Toxicita148562301075096136157200220250294
se180162301074289
liší19116230107284883103
mezi343763010773116153173
CTLA-453376301075095137191218264
inhibitory81776301071663111129178198226272299342
a1176763010740
PD-1/PD-L11233763010745101131169196242299328370407
inhibitory,166076301071663111130179198226272299342354
signifikantně34390301073453103152171196217255298347375424469
nejvyšší83190301074893113155199234268287
je113890301071862
v1219903010741
případě12789030107507797148190241285
kombinační158290301073886161212232281322363412432
léčby.343104301071965108159200213
K5781043010753
nejčastějším6521043010756102123165208243273317337372391467
irAE1140104301072755105149
patří13101043010758101130158179
kožní1510104301074695132183203
toxicita1734104301073684124145187207236280
(exantém,343118301072467109152202231275351368
pruritus),732118301075887137165186216266300323338
GIT1091118301076586131
toxicita1243118301073684124145187207237280
(průjem,1544118301073284113163183229305322
kolitida),18871183010746963431323010719386787137179202216
endokrinní580132301075099149199238267287336385404
toxicita1005132301073482121141182202231273
(hypopituitarismus,1298132301073181120172222273293322371390419461489509542617665699716
hypofyzitida,214162301074989141192218263303324353374424467484
hypotyreóza,264662301075697149200229273302346397434478495
insuficience316262301072776111160185206248268313363405450
nadledvin),363362301075698150214176301071965117160181230253268
hepatotoxicita2430763010757102154197226274303351391412454474503546
(elevace29977630107327596142184227269313
transamináz,333276301073564107157191235311331380423461480
hepatitida)214190301074996148192221241271292344387410
a2573903010749
pneumonitida.2644903010759110156206283334385405435456507550568
U3234903010765
stejného332190301074273118138189235286337
pacienta36799030107591032141104301074060105155183226
se2387104301074287
může25031043010774123161205
vyvinout2729104301074893138159208258307337
více3087104301074869110154
irAE.3262104301072654104147164
Ačkoliv34471043010761101140189210229272
je3740104301072672
poměrně21411183010750100175220247297342
dobře25031183010756105156184228
znám2751118301074393135209
počátek29811183010756106148190218262301
a33021183010748
délka33711183010756101121159202
trvání3594118301073562107150198218
irAEs214113230107194797140177
u23391323010756
jednotlivých2416132301072772124174224253273293336380422471
typů2908132301073680133183
toxicity,3112132301073584123144186206235279292
není34251323010757103153172
jasný3618132301072869104154194
bezpečný393962301075096134185231273322361
interval43216230107176694137165210252272
od461362301074798
ukončení473162301074887135185226269318337
léčby508962301071863105155196
a5304623010741
nejsou536562301074893113146196245
známy393976301073788131207248
prediktivní420876301075887132185205245277298341392412
biomarkery464276301075879129206249277318363391437
pro510076301075887136
jejich52587630107277394114156206
výskyt.548676301074994393990301073472116148165
Pro412590301074976124
léčbu426990301072368110160210
nežádoucích449990301075398136179229278327369388429478
účinků499890301075193112161200249
se526790301073883
kromě537190301074271119194239
spolupráce3939104301073484134154203253281323365408
onkologa4369104301074898136185205254305347
s47361043010735
příslušnými479310430107507898131151199233282321397416
specialisty5230104301073585131173192234253273306336380
jeví3939118301071964105126
jako408511830107175897145
zásadní4251118301073477111154204253272
časné4542118301074082116164209
zahájení4772118301073477126167187232281300
léčby5093118301071761103153194
steroidy,5307118301073261105132180200250291303
popřípadě39391323010750100151178198249291342386
jinými434613230107204088128203223
imunosupresivy.4589132301072094143192241276323374402446480499541585598
LITERATURA344156001234978134189250318368438498567
1.34317200853648
Büchler40417210833573105143159193215
T.63217210833241
Imunoonkologická68917210831270108146184223261291328344382422437469499533
léčba12371721083124780119152
inhibitory14041721083125088103142158180217239273
kontrolních169017210832967105127148185201239254286324
bodů.34318210833977117154167
Acta5251821083417296129
medicinae67018210835792131147179194232264299
2019;98418210833468100130143
1:114218210833543
80–82.120118210833469107143177189
2.34319200853652
Lakomý41019210833771102140199230
R,65619210834155
Poprach72719210834178118140173206245
A.98719210834762
Nežádoucí107019210834581110144184223261294309
účinky13951921083437591129160194
moderní161019210835897137172194233249
imunoterapie1874192108320791173432021083387698131153186225240275
a633202108337
jejich685202108320557085117155
řešení8552021083266086121159174
v1045202108336
klinické10962021083355166104119151181216
praxi.13272021083436598129145158
Klin15002021083405771109
Onkol162920210834786116154170
2015;181420210833973105135146
81975202108339
28(Suppl4):3432121083346887119156195235251286303315
4S103–4S114.6732121083346596128161197234265296323354367
3.34322200853649
Johnson4032221083246198135160197234
DB,6482221083458092
Chandra75122210833976107143181201233
S,99522210833244
Sosman10502221083326995151182218
JA.12802221083236276
Immune137022210831168124160197231
Checkpoint161222210833976110141170209247261297318
Inhibitor1944222108312483432321083375290105126162183
Toxicity5372321083336695110141155177210
in76123210831249
2018.8212321083346898129141
JAMA.97423210832463117158172
201811582321083346798128
Oct129723210834779102
23;14112321083346878
320(16):15012321083346599117148178196207
1702–1703.17192321083346395127160190219251283295
4.34324200853651
Noha40724210834583122154
AW,57424210834197107
Alshawa6942421083415783120153203236
A,94424210834155
Suarez-Almazor101224210833370102124158187209250266323356385422444
ME.146924210835588101
Adverse158424210834179112146167195230
Events18272421083336499137158186
in34325210831452
Cancer40725210834072109141174195
Immunotherapy.61725210831269126163201238260297332353385424454464
In:10962521083124961
Naing,11702521083447690128166179
J.136425210832133
Hajjar14102521083437590106137158
(eds.).15832521083164887113126144155
Immunotherapy,1753252108312691261632002383432621083215892113144182213222
Advances57726210834077109141177209241267
in85926210831148
Experimental91926210833263102136157171228262299319351366
Medicine129626210835488126141172186223257
and156426210833269106
Biology16822621083355086102139177208
995.190226210833367101112
5.34327200853650
Postow4082721083357299122159210
MA,63227210835597111
Sidlow7572721083334886102140191
R,96227210833650
Hellmann10262721083447995110168200238276
MD.1317272108354100111
Immune-related144427210831471129167205240263285319335367389422462
adverse1921272108331703432821083326687114149
events50528210833466100138159187
associated7052821083315884123155170202224257297
with10152821083506588126
immune115628210831270128165203238
checkpoint140728210833169103136166206245260298320
blockade.17392821083395593125155189228262275
N343292108345
Engl40329210833370109125
J543292108324
Med.58329210835489129142
2018;74029210833468100131143
378(2):8992921083346699118152170182
158–168.10962921083356599136167198233247
6.34330200853753
Shoushtari41230210833877116156183222244278300316
AN,74430210834794107
Friedman8673021083385975111151211244283
CF,11663021083468086
Navid-Azarbaijani127330210834679112128168191234266300322363397413428461500516
P,180530210834146
et186730210834063
al.19463021083385468
Measuring34331210835490121148185206222260299
toxic6573121083225989104136
effects8093121083335372106139163191
and101531210833270109
time11393121083223795130
to128431210832259
treatment13583121083214377109130189224262283
failure1657312108318516681119140174
for18473121083185577
nivolumab1939312108338533433221083326985123180213252
plus6113221083395592119
ipilimumab745322108316557086101158196254286325
in108632210831553
melanoma.115632210835792108140178216274307320
JAMA149132210832666121163
Oncol.167132210834785117154170183
2018;187132210833468100131143
4(1):3433321083345485100112
98–101.47033210833469106137168200210
7.34334200853544
Weber39834210835689127161182
JS,5943421083215264
Hodi67034210834481119134
FS,8163421083316274
Wolchok90234210835792107138175212242
JD,11593421083216576
et124734210833355
al.13133421083324659
Safety13843421083326382115137169
profile15653421083385995112129143177
of175434210833755
nivolumab1821342108337518311913417134335210835788127
monotherapy:48235210835795132170191229263284316355385398
a893352108331
pooled93635210833977115130164203
analysis115235210833168100115146173187213
of137735210833756
patients14453521083387092106141178199226
with16833521083506687125
advanced18203521083327010213417234336210833165104
melanoma.46336210835792108140178216275307320
J799362108324
Clin8383621083405570108
Oncol.96136210834786118155171184
2017;116036210833468100130139
35(7):13153621083346784119139151
785–792.148136210833467101138169203236248
8.214117200853652
Naidoo22081721083457792131169208
J,243117210832436
Wang248217210835788126165
X,266217210833851
Woo272817210835894133
KM,287517210833592105
et299517210833456
al.30661721083324760
Pneumonitis314117210833573108145203241280295317333359
in351517210831452
patients35821721083387193108143181203230
treated21411821083224377109131164204
with23591821083516689127
anti-programmeddeath-1/programmed250018210833270911071291691902282672883213794374725125515866176396777007317527908128498889109431000105810931133
death364718210833873105127165
ligand21411921083153069101139178
12334192108334
therapy.23841921083216095116149188219229
J2629192108324
ClinOncol.26681921083405570108156195227264280293
2017;297619210833468100129139
35(7):31301921083356885120139151
709–717.329719210833467102140171204233239
9.214120200853649
Faje22052021083326277112
AT,23312021083417079
Sullivan24252021083327085100115148180219
R,265820210833549
Lawrence272220210833165115137171209242275
D,301220210834556
et308320210833356
al.31532021083324860
Ipilimumab-induced322920210831453688499156194252284323347363401440477510543583
hypophysitis:214121210833868108147187225256283298320335361374
a2530212108336
detailed25852121083387395128143158193233
longitudinal28332121083185795134149172210249264302334349
analysis319821210833573105121153180194221
in343421210831856
a3505212108336
large35562121083195172110145
cohort37172121083347121412221083387697122
of228122210833757
patients23562221083387193108143181203230
with26042221083516689127
metastatic274922210835792115147174197230252267299
melanoma.306622210835792108140178216275307320
J3402222108327
Clin34472221083395570107
Endocrinol35702221083357311215018320422021412321083387692
Metab.224823210835590112145184196
2014;246023210833468100131143
99(11):26182321083346989120148162174
4078–4085.280823210833470102136173210245281315327
10.21412420085367085
Suzman22412421083327099158190228
DL,24842421083467892
Pelosof25912421083356984123149188207
L,281324210833245
Rosenberg287424210833574100135173212248269307
A,319724210834155
Avigan32682421083417187126158196
MI.34792421083557084
Hepatotoxicity35782421083447911915217321021412521083215787102133148169202
of235525210833756
immune242625210831168124161198232
checkpoint267125210833068102134163202240255292313
inhibitors:29992521083124986100138153175211232259271
an328225210833168
evolving336225210833465102117149164201239
picture36132521083395385108145166199
of214126210833756
risk2212262108318335988
associated23132621083315783121153168199221254293
with26182621083506688125
a2756262108331
vital28002621083314769101116
class29282621083314678104130
of307126210833755
immunotherapy314126210831269127164201239260298332353386424455
agents.360926210833169104141162190203
Liver21412721083314779114135
Int.2291272108315537488
2018;239427210833468100131143
38(6):25532721083346887121139151
976–987.27192721083346799137171206239245
11.21412820085366678
Moslehi223428210835493120135170208223
JJ,24722821083244860
Salem25472821083336681116174
JE,27362821083245770
Sosman28222821083327097155187225
JA,30622821083246478
Lebrun-Vignes315628210833165104126164202225261277316354389416
B,358728210833548
Johnson365028210832462101139214129210832664103
DB.22582921083458295
Increased23682921083145284105139171198233272
reporting26562921083195392131153177193231270
of294029210833756
fatal30122921083175072105120
immune314829210831371129166204239
checkpoint340129210833270105137167208247262300322
inhibitor-associated37382921083135121413021083375291107129166188207240266293331363379410432466505
myocarditis.265930210835788126158191212250265288303329342
Lancet.301430210833265103135169191204
2018;323130210833468100131143
391(10124):33873021083346799114146177209239271288300
933.370030210833467100112
12.21413120085366884
Zimmer223831210833853111169204225
L,247731210833145
Goldinger25353121083448399138153191230265286
SM,283531210833286100
Hofmann294931210834482101160193231269
L,323131210833245
et329031210833456
al.33603121083324760
Neurological,343431210834580118139176192230270285317350365377
respiratory,21413221083215582120136157190212249270304314
musculoskeletal,246932210835795121153191206245271301335351386408441456469
cardiac29513221083316485124139171203
and316832210833169108
ocular329032210833770108123155176
side-effects34823221083243978113136172192211245278302330
of214133210833757
anti-PD-122133321083327091107129166211234265
therapy.24933321083226095116149189220230
Eur27383321083336991
JCancer.28443321083246598136168202223233
2016;309333210833468100131143
60:32513321083357083
210–225.33493321083356697135167202237249
13.21413420085366883
Pundole223734210833572110149187203238
X,248834210833852
Sarangdhar25533421083326586119157196235273305326
M,289234210835568
Suarez-Almazor,297334210833370102123157187208250265323355384422443453
ME.343934210835588101
Rheumatic35533421083357410914620423621413521083223769
and222535210833270109
musculoskeletal235035210835794121153191206244271301335351385408441456
adverse282135210833271104138159187222
events305835210833466100139160188
associated32613521083325985123156171203225259298
with35753521083506688126
immune371735210831472214136210835795133168
checkpoint232236210833169104137167207246261299321
inhibitors:26583621083125088103142158180217239266278
data29493621083387192125
mining308736210835773110125163202
of330236210833857
the33743621083195893
us348036210833763
food35583621083165493132
and370336210833270109
drug39391721083386098138
administration409217210833777135150189204230254275309330346384423
adverse453117210833776109144165193228
event477417210834072107145167
reporting49571721083266099139160185201239278
system.52511721083316491115149207221
Annals548717210836210039391821083387085111
of406518210833757
the41371821083215994
Rheumatic424618210833674109147205237259274306
Diseases45671821083456187122154180215242
2018;482418210833468100131143
77(Suppl49821821083346985117154193233249
2):52461821083345264
147.2–148.53251821083346597103139173204235271285
14.39391920085366984
Barbosa40401921083356889129168195228
NS,42841921083457790
Wetter439019210835791113137171192
DA,45981921083468599
Carylin47141921083407294128144159196
M,492719210835467
et501119210833456
al.50821921083334861
Scleroderma51591921083336580115136174213248269328360
Induced553519210831553393920210833977110144185
by413920210834577
Pembrolizumab:423120210834176135175197235251266296335394427467480
A4727202108346
Case478920210834680107142
Series.49472021083387496112147175189
Mayo515720210835588120158
Clin53312021083466177115
Proc.546220210834162100134147
2017;393921210833468100129139
92(7):40942121083346784119138150
1158–1163.42602121083346191126163193221252286299
15.39392220085366780
Wang403122210835787124162
YD,42042221083368190
Salem43062221083336478112168
JE,44862221083245668
Cohen456622210834075112146183
JV,47612221083245967
et484022210833454
al.49062221083324658
Fatal49762221083326080112126
Toxic51142221083326594108138
Effects52642221083335069102134156183
Associated545922210834167921293939232108331457696129167
With41242321083587294131
Immune426923210831875131168205238
Checkpoint452523210834077111142171210248262299319
Inhibitors:48582321083185592106144158179215235261272
A5148232108341
Systematic52032321083366591113145202233253267298
Review55152321083397339392421083324679129
and408124210833168106
Meta-analysis.419924210835588109141162192229260274304330343368380
JAMA459324210832362116156
Oncol.476224210834784115150165176
2018;49512421083346797127138
4(12):51012421083345283111128138
1721–1728.52522421083346295125156186214247279291
16.39392520085366985
Kyi40382521083356480
C,413125210834053
Hellmann41982521083447994110167200238276
MD,4487252108354100111
Wolchok461225210835794110142180218249
JD,48762521083226879
Chapman496925210834077110149207239277
PB,52602521083357083
et535625210833457
al.54262521083324760
Opportunistic55002521083478639392621083387798122159197211237260275306
infections42602621083124968102134158173210248274
in454926210831249
patients46102621083397193107142179200227
treated48522621083194074105127160199
with50632621083506587125
immunotherapy520326210831269126163201238260297332353385393927210833970
for40242721083195678
cancer.411727210833164102134168189200
J4332272108324
Immunother437227210831472130168206244266304339360
Cancer474727210834073111143177198
2014;496127210833468100131143
18(2):51192721083346584118136148
19.52822721083346576
17.39392820085366876
Arriola40322821083416284100138154186
E,423328210833447
Wheater429728210835796131163185218240
M,455328210835568
Krishnan4638282108335577399137175207245
R,490028210833549
Smart496528210833391123145169
J,514928210832638
Foria52022821083347293109141
V,535928210833645
Ottensmeier54212821083477095128166393929210832683118132167188
C.413929210834053
Immunosuppression420729210831269126164201239265302341380401435461487502539577
for48002921083155274
ipilimumab-related488929210831250668195152190247279317341362396411443465498537
toxicity54412921083195585101132147393930210832255
can400730210833163101
cause412130210833164101127162
pneumocystis429530210833977112149207245277310337360375401
pneumonia470930210833877111149206244282297329
but50513021083387699
spare51623021083266598119152
antitumor53273021083327091106128166223261283
immune393931210831572130168206241
control.419531210833673112133155192208221
Oncoimmunology443631210834786118155170228286323361400416454493525
2015;497731210833973105135145
4(10):51383121083395890121140152
e1040218–530531210833969100136172205237268305
e1040218.39393221083346495131167200232263276
18.39393320085356883
National40343321083447596111148185216231
Comprehensive427733210833975132170191224261295332357371403436
Cancer472533210833971108139172192
Network.492933210834478100151188209238252
Prevention51933321083355588119152189210225261299
and550433210833168106
treatment39393421083224377109131189224262284
of423834210834160
cancer-related431334210833568106138172193213235269284317338372412
infections,47403421083185675109142166181219258284297
version50533421083356990117132170209
1.527734210833847
2018,534034210833771103134147
December550634210834581393935210833165123162198219
1,417335210833543
2017.423235210833468100130136
Dostupné438335210834684111134172211250285
z:468335210832942
http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf474135210833859841231351621832342873403513904224534915045425646026286666877257447788058328473939362108337761081231491752132512823093243563714034414785175325585846226616817057217597788128458698849229619871001104010801099